NICE Is Back In Business, And So Are Its Critics
This article was originally published in The Pink Sheet Daily
Executive Summary
UK Prime Minister David Cameron is petitioned to reverse NICE's rejection of Celgene's Vidaza, on the same day that NICE resumes issuing guidelines.
You may also be interested in...
Exelixis Building A Pipeline Out Of A Product, Unveils Cabozantinib Activity Across Tumor Types At ASCO
Exelixis Inc. is set to file the first NDA for its dual MET/VEGF2 inhibitor cabozantinib by the end of the year, but as that project winds down, plans for a suite of new indications are in the works as the company tries to leverage its asset as fully as possible.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.